Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2022 | $46.00 → $21.00 | Overweight | Cantor Fitzgerald |
| 11/12/2021 | $54.00 → $40.00 | Outperform | SVB Leerink |
| 8/17/2021 | $55.00 → $53.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $58.00 | Buy | Craig Hallum |
15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
The "Believe it!" Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (NASDAQ:FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005106/en/ SCD occurs in one in every 365 Black Americans and affects an estimated 100,000 individuals in the U.S. 1 alone, according to the Centers for D
Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t
Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024
Cantor Fitzgerald resumed coverage of Forma Therapeutics with a rating of Overweight and set a new price target of $21.00 from $46.00 previously
SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $40.00 from $54.00 previously
HC Wainwright & Co. reiterated coverage of Forma Therapeutics Hldgs with a rating of Buy and set a new price target of $53.00 from $55.00 previously
SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t
Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024
Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirtiesIf approved, olutasidenib would be Ri
Novo Nordisk A/S (NYSE:NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes. In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study. Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing. The news adds to ONWARDS trial readouts dating back to April.
Within the last quarter, Forma Therapeutics Hldgs (NASDAQ:FMTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 3 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Forma Therapeutics Hldgs has an average price target of $20.25 with a high of $21.00 and a low of $20.00. Below is a summary of how these 4 analysts rated Forma Therapeutics Hldgs over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings,
Upgrades Guggenheim upgraded the previous rating for Salesforce Inc (NYSE:CRM) from Sell to Neutral. For the second quarter, Salesforce had an EPS of $1.19, compared to year-ago quarter EPS of $1.48. The stock has a 52-week-high of $256.87 and a 52-week-low of $150.87. At the end of the last trading period, Salesforce closed at $153.53. For Okta Inc (NASDAQ:OKTA), Guggenheim upgraded the previous rating of Sell to Neutral. In the second quarter, Okta showed an EPS of $0.10, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $226.49 and a 52-week-low of $58.12. Okta closed at $60.60 at the end of the last trading period. For Advent Technologies
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock pursuant to Inducement Non-Qualified Stock Option Agreements (the "Stock Options") and 79,000 and 39,000 restricted stock units, respectively, pursuant to Inducement Restricted Stock Unit Agreements (the "RSUs," and together with the Stock Options, the "Inducement Grants"). On June 30, 2022, Forma announced the appointment
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the company's inaugural chief patient officer and senior vice president. In this role, Dr. Osunkwo will be responsible for realizing Forma's vision to transform the lives of patients by improving access and care through partnerships with global patient and community stakeholders. She will join Forma in the first quarter of 2022. "This appointment of a chief patient officer boldly represents our commitment to advancing both patient access and care a
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer. In this role, Dr. Bishop will lead chemistry, manufacturing and control (CMC)-related functions and quality, encompassing Forma's early pipeline through commercial product. "We are fortunate to welcome John to Forma at this pivotal time in Forma's history," said Frank Lee, chief executive officer of Forma. "John's extensive expertise in small-molecule pharmaceuticals and proven track record as a leader will help to e